View Future GrowthInvion 過去の業績過去 基準チェック /06Invionの収益は年間平均-47.1%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間8.8% 16.7%割合で 減少しています。主要情報-47.15%収益成長率-41.47%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率-16.69%株主資本利益率-184.03%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0 in FY 2023)Full year 2024 results: AU$0.001 loss per share (further deteriorated from AU$0 in FY 2023). Revenue: AU$3.74m (down 8.8% from FY 2023). Net loss: AU$5.63m (loss widened 249% from FY 2023).Reported Earnings • Oct 02Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.10m (up 25% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.14m (up 26% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)First half 2023 results: EPS: AU$0 (in line with 1H 2022). Revenue: AU$1.95m (up 50% from 1H 2022). Net loss: AU$830.7k (loss narrowed 21% from 1H 2022).Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0 (vs AU$0 in FY 2021)Full year 2022 results: EPS: AU$0 (vs AU$0 in FY 2021). Revenue: AU$3.29m (up 41% from FY 2021). Net loss: AU$2.24m (loss widened 51% from FY 2021).Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0 (vs AU$0 in 1H 2021). Revenue: AU$1.30m (up 4.4% from 1H 2021). Net loss: AU$1.05m (loss widened 23% from 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates.すべての更新を表示Recent updatesBoard Change • May 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Non-Executive Director Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 24Invion Limited, Annual General Meeting, Nov 26, 2025Invion Limited, Annual General Meeting, Nov 26, 2025.お知らせ • Oct 10Invion Limited announced that it expects to receive AUD 0.782254 million in fundingInvion Limited announced private placement to issue 71,114 Zero Coupon Unsecured Convertible Notes at a price of AUD 11 each for aggregate gross proceeds of AUD 782,254 on October 10, 2025. The Notes will have a maturity date of February 28, 2026 and a conversion price of AUD 0.11. The company will pay y the lead manager, Blue Ocean, a management fee equivalent to 3% of the total proceeds raised under the Offer and a 3% selling fee calculated on the total proceeds raised under the Offer, less Chairman’s list investors. The transaction is expected to close on or about October 16, 2025. The transaction will include participation from Summit Biotech Fund and other sophisticated investors.お知らせ • Jun 13Invion Limited has announced a Derivatives Offering in the amount of AUD 1 million.Invion Limited has announced a Derivatives Offering in the amount of AUD 1 million. Security Name: Loyalty Option Security Type: Equity Option Securities Offered: 66,666,667 Price\Range: AUD 0.015 Transaction Features: Rights OfferingBoard Change • Dec 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Non-Executive Director Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 28Invion Limited Announces Change of Company SecretaryInvion Limited announced the appointment of Ms. Melanie Leydin as Company Secretary, effective immediately. Mr. Phan will resign as Company Secretary of Invion, effective immediately. Invion further advised that, in accordance with Listing Rule 12.6 and with immediate effect, Ms. Leydin is the person responsible for communications with ASX in relation to Listing Rule matters.お知らせ • Oct 15Invion Limited, Annual General Meeting, Nov 14, 2024Invion Limited, Annual General Meeting, Nov 14, 2024.Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0 in FY 2023)Full year 2024 results: AU$0.001 loss per share (further deteriorated from AU$0 in FY 2023). Revenue: AU$3.74m (down 8.8% from FY 2023). Net loss: AU$5.63m (loss widened 249% from FY 2023).New Risk • Aug 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.03m (US$8.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Share price has been highly volatile over the past 3 months (104% average daily change). Earnings have declined by 0.9% per year over the past 5 years. Market cap is less than US$10m (€8.03m market cap, or US$8.93m). Minor Risks Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$3.0m).New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Share price has been highly volatile over the past 3 months (104% average daily change). Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$2.9m). Market cap is less than US$100m (€16.0m market cap, or US$17.6m).お知らせ • Jul 31Invion Limited Announces Change of Company SecretaryInvion Limited announced the appointment of Mr. Tai Phan as Company Secretary, effective immediately. Mr. Phan has over 20 years' experience as a lawyer, Company Secretary, and corporate governance and compliance professional. He has worked directly with Boards and executive management of several ASX-listed entities (i.e. Zip Co Limited, Westpac Banking Corp, HT&E Limited, and Yancoal Australia Ltd) and numerous unlisted companies across multiple industries. He has experience in the IPO listing process for the ASX, has been appointed an external consultant for AUSTRAC and as the Head of AsiaPac Compliance (for Travelex and Munich Re). Ms Claire Newstead-Sinclair will resign as Company Secretary of Invion, effective immediately.New Risk • Jul 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (118% average daily change). Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$3.0m). Market cap is less than US$100m (€16.5m market cap, or US$17.8m).お知らせ • Oct 30Invion Limited, Annual General Meeting, Nov 29, 2023Invion Limited, Annual General Meeting, Nov 29, 2023, at 13:00 AUS Eastern Standard Time. Agenda: To consider Adoption of Remuneration Report; to consider Re-election of Mr. Alistair Bennallack as a Director of the Company; and to consider Approval of 10% Placement Facility.Reported Earnings • Oct 02Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.10m (up 25% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.14m (up 26% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)First half 2023 results: EPS: AU$0 (in line with 1H 2022). Revenue: AU$1.95m (up 50% from 1H 2022). Net loss: AU$830.7k (loss narrowed 21% from 1H 2022).Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0 (vs AU$0 in FY 2021)Full year 2022 results: EPS: AU$0 (vs AU$0 in FY 2021). Revenue: AU$3.29m (up 41% from FY 2021). Net loss: AU$2.24m (loss widened 51% from FY 2021).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0 (vs AU$0 in 1H 2021). Revenue: AU$1.30m (up 4.4% from 1H 2021). Net loss: AU$1.05m (loss widened 23% from 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates.Buying Opportunity • Feb 15Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 48%. The fair value is estimated to be AU$0.0077, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% per annum over the last 3 years. Earnings per share has grown by 13% per annum over the last 3 years.Board Change • Nov 23Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). CEO & Executive Chairman Thian Chew is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.収支内訳Invion の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:7C8 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 250-114030 Sep 250-103030 Jun 250-93031 Mar 251-84031 Dec 241-76030 Sep 243-66030 Jun 244-66031 Mar 244-44031 Dec 234-12030 Sep 234-22030 Jun 234-22031 Mar 234-22031 Dec 224-22030 Sep 224-23030 Jun 223-23031 Mar 223-23031 Dec 212-22030 Sep 212-22030 Jun 212-12031 Mar 213-12031 Dec 203-12030 Sep 203-12030 Jun 203-13031 Dec 195-24030 Sep 194-24030 Jun 194-34031 Dec 182-12030 Sep 181-12030 Jun 181-11031 Mar 180-61031 Dec 170-61030 Sep 170-41030 Jun 170-21031 Mar 17001031 Dec 16022030 Sep 160-13030 Jun 160-43031 Mar 160-84031 Dec 150-114030 Sep 150-124030 Jun 150-1350質の高い収益: 7C8は現在利益が出ていません。利益率の向上: 7C8は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 7C8は利益が出ておらず、過去 5 年間で損失は年間47.1%の割合で増加しています。成長の加速: 7C8の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 7C8は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 16.1% ) と比較することは困難です。株主資本利益率高いROE: 7C8は現在利益が出ていないため、自己資本利益率 ( -184.03% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 18:24終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Invion Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0 in FY 2023)Full year 2024 results: AU$0.001 loss per share (further deteriorated from AU$0 in FY 2023). Revenue: AU$3.74m (down 8.8% from FY 2023). Net loss: AU$5.63m (loss widened 249% from FY 2023).
Reported Earnings • Oct 02Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.10m (up 25% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).
Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.14m (up 26% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).
Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)First half 2023 results: EPS: AU$0 (in line with 1H 2022). Revenue: AU$1.95m (up 50% from 1H 2022). Net loss: AU$830.7k (loss narrowed 21% from 1H 2022).
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0 (vs AU$0 in FY 2021)Full year 2022 results: EPS: AU$0 (vs AU$0 in FY 2021). Revenue: AU$3.29m (up 41% from FY 2021). Net loss: AU$2.24m (loss widened 51% from FY 2021).
Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0 (vs AU$0 in 1H 2021). Revenue: AU$1.30m (up 4.4% from 1H 2021). Net loss: AU$1.05m (loss widened 23% from 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates.
Board Change • May 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Non-Executive Director Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 24Invion Limited, Annual General Meeting, Nov 26, 2025Invion Limited, Annual General Meeting, Nov 26, 2025.
お知らせ • Oct 10Invion Limited announced that it expects to receive AUD 0.782254 million in fundingInvion Limited announced private placement to issue 71,114 Zero Coupon Unsecured Convertible Notes at a price of AUD 11 each for aggregate gross proceeds of AUD 782,254 on October 10, 2025. The Notes will have a maturity date of February 28, 2026 and a conversion price of AUD 0.11. The company will pay y the lead manager, Blue Ocean, a management fee equivalent to 3% of the total proceeds raised under the Offer and a 3% selling fee calculated on the total proceeds raised under the Offer, less Chairman’s list investors. The transaction is expected to close on or about October 16, 2025. The transaction will include participation from Summit Biotech Fund and other sophisticated investors.
お知らせ • Jun 13Invion Limited has announced a Derivatives Offering in the amount of AUD 1 million.Invion Limited has announced a Derivatives Offering in the amount of AUD 1 million. Security Name: Loyalty Option Security Type: Equity Option Securities Offered: 66,666,667 Price\Range: AUD 0.015 Transaction Features: Rights Offering
Board Change • Dec 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Non-Executive Director Melanie Leydin was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 28Invion Limited Announces Change of Company SecretaryInvion Limited announced the appointment of Ms. Melanie Leydin as Company Secretary, effective immediately. Mr. Phan will resign as Company Secretary of Invion, effective immediately. Invion further advised that, in accordance with Listing Rule 12.6 and with immediate effect, Ms. Leydin is the person responsible for communications with ASX in relation to Listing Rule matters.
お知らせ • Oct 15Invion Limited, Annual General Meeting, Nov 14, 2024Invion Limited, Annual General Meeting, Nov 14, 2024.
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0 in FY 2023)Full year 2024 results: AU$0.001 loss per share (further deteriorated from AU$0 in FY 2023). Revenue: AU$3.74m (down 8.8% from FY 2023). Net loss: AU$5.63m (loss widened 249% from FY 2023).
New Risk • Aug 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.03m (US$8.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Share price has been highly volatile over the past 3 months (104% average daily change). Earnings have declined by 0.9% per year over the past 5 years. Market cap is less than US$10m (€8.03m market cap, or US$8.93m). Minor Risks Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$3.0m).
New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Share price has been highly volatile over the past 3 months (104% average daily change). Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$2.9m). Market cap is less than US$100m (€16.0m market cap, or US$17.6m).
お知らせ • Jul 31Invion Limited Announces Change of Company SecretaryInvion Limited announced the appointment of Mr. Tai Phan as Company Secretary, effective immediately. Mr. Phan has over 20 years' experience as a lawyer, Company Secretary, and corporate governance and compliance professional. He has worked directly with Boards and executive management of several ASX-listed entities (i.e. Zip Co Limited, Westpac Banking Corp, HT&E Limited, and Yancoal Australia Ltd) and numerous unlisted companies across multiple industries. He has experience in the IPO listing process for the ASX, has been appointed an external consultant for AUSTRAC and as the Head of AsiaPac Compliance (for Travelex and Munich Re). Ms Claire Newstead-Sinclair will resign as Company Secretary of Invion, effective immediately.
New Risk • Jul 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (118% average daily change). Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$3.0m). Market cap is less than US$100m (€16.5m market cap, or US$17.8m).
お知らせ • Oct 30Invion Limited, Annual General Meeting, Nov 29, 2023Invion Limited, Annual General Meeting, Nov 29, 2023, at 13:00 AUS Eastern Standard Time. Agenda: To consider Adoption of Remuneration Report; to consider Re-election of Mr. Alistair Bennallack as a Director of the Company; and to consider Approval of 10% Placement Facility.
Reported Earnings • Oct 02Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.10m (up 25% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).
Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.14m (up 26% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022).
Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)First half 2023 results: EPS: AU$0 (in line with 1H 2022). Revenue: AU$1.95m (up 50% from 1H 2022). Net loss: AU$830.7k (loss narrowed 21% from 1H 2022).
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0 (vs AU$0 in FY 2021)Full year 2022 results: EPS: AU$0 (vs AU$0 in FY 2021). Revenue: AU$3.29m (up 41% from FY 2021). Net loss: AU$2.24m (loss widened 51% from FY 2021).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0 (vs AU$0 in 1H 2021). Revenue: AU$1.30m (up 4.4% from 1H 2021). Net loss: AU$1.05m (loss widened 23% from 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates.
Buying Opportunity • Feb 15Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 48%. The fair value is estimated to be AU$0.0077, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% per annum over the last 3 years. Earnings per share has grown by 13% per annum over the last 3 years.
Board Change • Nov 23Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). CEO & Executive Chairman Thian Chew is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.